Oncological Outcome of Docetaxel-Based Chemotherapy for Men with Metastatic Castration-Resistant Prostate Cancer.
To retrospectively review the oncological outcome of docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). The present study included 68 patients with mCRPC who were treated with 3-weekly docetaxel (75 mg/m2) plus prednisone between 2010 and 2014. The prognostic significance of several clinicopathologic factors in these patients were analyzed. The endpoints of oncological outcome were overall survival (OS). The effect of clinical variables on OS was statistically analyzed by a log-rank test or Cox regression with hazard ratios. All analyses were performed using a 0.05 level of significance. In these 68 patients, the median age and serum value of prostate-specific antigen (PSA) prior to docetaxel-based chemotherapy were 69 years and 173 ng/ml, respectively. Of these patients, PSA decline ≥50% was observed in 46 patients (67.6%). The OS and progression-free survival were 25.4 and 11.7 months, respectively. Of several factors examined, univariate analysis identified PSA at diagnosis mCRPC, PSA at diagnosis of mCRPC, PSA at first cycle of CMT ≥150 ng/mL, number of CMT response ≤2 cycle as significant predictors of OS, of which only PSA at first cycle of CMT ≥150 ng/mL appeared to be independently related to poor OS on multivariate analysis. Oncologic outcomes in mCRPC patients receiving docetaxel-based chemotherapy is generally favorable and only PSA at first cycle of CMT more than 150 ng/mL appeared to be independently related to poor OS on multivariate analysis.